In a different phase 1b trial, advanced-stage HCC patients were divided into two groups: one combination therapy group received atezolizumab (ICI, anti-PD-L1 antibody) 1200 mg with bevacizumab (anti-VEGF antibody) 15 mg/kg, both on the first day of 21-day cycles, while one monotherapy group received atezolizumab alone [59]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.